Referencias: Guía detallada del linfoma no Hodgkin

American Cancer Society. Cancer Facts & Figures 2012. Atlanta, Ga: American Cancer Society; 2012.

Dunleavy K, Wilson WH. Diagnosis and treatment of non-Hodgkin lymphoma (aggressive). In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Elsevier; 2009:1293−1302.

Evens AM, Winter JN, Gordon LI, et al. Non-Hodgkin lymphoma. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach. 13th ed. Lawrence, KS: UBM Medica; 2010:739−794.

Friedberg JW, Mauch PM, Rimsza LM, Fisher RI. Non-Hodgkin's lymphomas. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008:2278−2292.

Gribben JG. Clinical manifestations, staging, and treatment of indolent non-Hodgkin's lymphoma. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Elsevier; 2009:1281−1292.

Hartge P, Smith MT. Environmental and behavioral factors and the risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:367−368.

Jaffe ES, Pittaluga S. The pathologic basis for the classification of non-Hodgkin's lymphoma. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Elsevier; 2009:1265−1280.

Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009;27:2983−2990.

Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States 1992-2001. Blood. 2006;107:265−276.

National Cancer Institute. Physician Data Query (PDQ). Adult Non-Hodgkin Lymphoma Treatment. 2011. Accessed at www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/healthprofessional on September 27, 2011.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. Version 4.2011. Accessed at www.nccn.org/professionals/physician_gls/pdf/nhl.pdf on September 27, 2011.

Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood. 2006;107:1255−1264.

Schuster SJ, Neelapu SS, Gause BL, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol. 2009;27:18s (suppl; abstr 2).

Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857−1861.

Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004;104:1258−1265.

Wilson WH, Armitage JO. Non-Hodgkin's Lymphoma. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff's Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:2371−2404.

Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006552.